Oct 29, 6:43 AM ET
Merck reported worldwide sales of $18.1 billion for the third quarter of 2026, representing a 5% increase compared to the same period in 2025. GAAP EPS was $2.04 and non-GAAP EPS was $2.49, both impacted by a one-time charge related to a global license agreement with SciBrunch. The company also narrowed and raised its full-year 2026 financial outlook for sales and non-GAAP EPS.
- Total worldwide sales reached $18.1 billion in Q3 2026, up 5% from $17.276 billion in Q3 2025.
- KEYTRUDA sales grew 6% to $8.6 billion, and WINREVAIR sales surged 93% to $694 million.
- Full-year 2026 sales outlook was raised to a range of $66.8 billion to $67.3 billion.
- Full-year 2026 non-GAAP EPS outlook was raised to a range of $2.77 to $2.82.
Read the filing on SEC.gov ↗
Oct 13, 12:36 PM ET
Merck & Co. said Paul J. Diaz, managing partner at Cressey & Company, will join its Board of Directors effective Nov. 1, 2026, bringing the board to 14 members. He will stand for election by shareholders in May 2027 and will serve on the Audit and Research Committees, and he will be paid as a non-employee director under the company's published compensation practices.
- Diaz joins the board effective Nov. 1, 2026, and will stand for shareholder election in May 2027.
- He was appointed to both the Audit Committee and the Research Committee.
- The board will have 14 members after his addition.
- Diaz previously served as president and CEO of Myriad Genetics, Inc. and Kindred Healthcare.
Read the filing on SEC.gov ↗
Aug 4, 6:47 AM ET
Merck reported second-quarter 2026 sales of $16.6 billion, up 5%, but a $2.31 per share charge for the Terns acquisition turned GAAP results to a loss of $0.54 per share, compared with EPS of $1.76 a year earlier. The company narrowed and raised its full-year sales outlook to $66.3 billion to $67.3 billion, but cut its non-GAAP EPS outlook to $2.66 to $2.76 from $5.04 to $5.16, reflecting one-time charges for the Terns and Cidara acquisitions.
- Q2 2026 sales were $16.6 billion, up 5% (4% ex-FX); KEYTRUDA/KEYTRUDA QLEX sales were $8.4 billion and WINREVAIR sales were $588 million, up 75%.
- Q2 2026 non-GAAP loss per share was $0.13, compared with non-GAAP EPS of $2.13 in Q2 2025.
- Full-year 2026 non-GAAP EPS outlook is $2.66 to $2.76, including $3.62 per share for Cidara and $2.31 per share for Terns one-time charges.
- Full-year 2026 sales outlook was raised to $66.3 billion to $67.3 billion from $65.8 billion to $67.0 billion.
Read the filing on SEC.gov ↗
May 22, 4:21 PM ET
On May 22, 2026, Merck & Co. closed an underwritten public offering of seven series of notes with a combined principal amount of $6.0 billion, maturing between 2028 and 2056. The filing describes the issuance terms and related legal documents but does not state how the company plans to use the proceeds.
- Seven note series totaling $6.0 billion, from a $500 million floating rate note due 2028 to a $1 billion 5.850% note due 2056
- Largest series is $1.5 billion of 5.200% notes due 2036
- Notes issued under a shelf registration statement filed March 19, 2024, and an indenture dated January 6, 2010, with U.S. Bank Trust National Association as trustee
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.